ZeroRISC Delivers Production-Grade Post-Quantum Cryptography for Open Silicon

10 Mar

Written By Alexandra Collingbourne

Alexandra Collingbourne

Monument Therapeutics Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis

Engine vroom as Abselion opens US base